At last, US nod for UCB's Bimzelx, and another possible blockbuster too

UCB (Euronext: UCB) has won two approvals from the US Food and Drug Administration, one for a new first-in-class rare disease med and another, for Bimzelx (bimekizumab-bkzx), bringing a new option for Americans with plaque psoriasis.

Belgium’s largest biotech, UCB generated revenues close to $6 billion last year, and both of the newly-approved products are believed by analysts to have blockbuster potential.

UCB has forecast that Bimzelx alone could bring in as much as $4.2 billion per year at peak.